Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of quinazoline compounds

A technology of quinazolines and compounds, applied in the field of medicine, can solve the problems of large drug resistance of adverse reactions, narrow use range, poor solubility of paclitaxel, etc.

Inactive Publication Date: 2010-12-29
XIANGBEI WELMAN PHARMA CO LTD +1
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The solubility of paclitaxel is very poor, the adverse reactions are large and drug resistance is easy to develop
Colchicines have demonstrated narrow use against cellular hyperproliferative disorders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of quinazoline compounds
  • Application of quinazoline compounds
  • Application of quinazoline compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Example 1 Effect of LJK-11 on Microtubule Polymerization

[0078] Experimental instrument: Tecan GENios Pro multifunctional microplate reader

[0079] Experimental reagents: Tubulin Polymerization Assay Kit (Cat.#CDS03 and BK006)

[0080] experimental method:

[0081] 1. Preheat the 96-well plate at 37°C for 30 minutes;

[0082] 2. Pre-cool tubulin polymerization buffer at 4°C:

[0083] General Tubulin Buffer (750μl): 80mM PIPES (pH6.9), 2mM Mgcl 2 , 0.5mM EGTA;

[0084] Tubulin Glycerol Buffer (250μl): 15% glycerol in General Tubulin Buffer;

[0085] GTP Stock (200mM, 10μl): 1mM GTP;

[0086] 3. Preheat 500μl General Tubulin Buffer to room temperature;

[0087] 4. Randomly divided into 5 groups: (1) Control group: add 5 μl General Tubulin Buffer to each well; (2) LJK-11 group: add 10 μl LJK-11 to each well, the final concentrations are 200 μM, 100 μM, 25 μM, 5 μM, 1 μM, incubate at 37°C for 2 minutes; (3) Colchicine group: pipette 10 μl colchicine and dissolve ...

Embodiment 2

[0092] Example 2 Effect of LJK-11 on human gastric cancer HGC cell cycle

[0093] Culture HGC cells in vitro, when the growth state is good, digest and inoculate 1×10 5 Cells were placed in a 6cm culture dish and adhered to the wall overnight. After the cells were in good condition, the medium was aspirated, and LJK-11 diluted with the medium was added to the final concentrations of 5 μM, 25 μM, and 50 μM, respectively, and the medium was added to the negative control wells, and cultured at 37°C for 24 hours. Changes in cell morphology were observed under a microscope. The cells were digested with trypsin (0.25% trypsin / 0.02% EDTA), gently blown down, transferred to a centrifuge tube, centrifuged at 2000rpm for 5min, washed twice with PBS, and centrifuged at 1000rpm for 5min. Slowly add 800 μl of 75% ethanol (pre-cooled at -20°C) to the cell pellet, and shake (Vortex) while dripping to make it form a single cell as much as possible. After fixing overnight at 4°C, centrifuge...

Embodiment 3

[0095] Example 3 Inhibition of Tested Drugs on the Growth of Various Tumor Cells

[0096] Human breast cancer MDA-MB-453 cells, human cervical cancer Hela cells, human lung cancer A549 cells, and human gastric cancer HGC cells were cultured in vitro. After the cells grow to the logarithmic growth phase, collect the cells, centrifuge at 1000rpm for 5 minutes, discard the supernatant, suspend with an appropriate amount of medium, and adjust the cell concentration to 3.5x10 3 / ml. The cell suspension was inoculated into a 96-well cell culture plate, 100 μl per well, placed in a cell culture incubator (37° C., 5% CO 2 ) for 24 h, and then the drug to be tested, LJK-11 (final concentrations of 1 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, 80 μM, 100 μM), LJK-4 (final concentration is 40 μM), LJK-6 (final concentration is 40 μM), LJK-12 (final concentration is 40 μM), LJK-13 (final concentration is 40 μM), the negative control group was added with a final concentration of 0.5% DMSO, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of drugs, in particular to application of quinazoline compounds. The invention discloses application of the quinazoline compounds shown in the general formula I or pharmaceutically acceptable salt, prodrugs or isomers thereof in preparing mitotic inhibitors. The quinazoline compounds shown in the general formula I or pharmaceutically acceptable salt, prodrugs or isomers have the effect of inhibiting tubulin polymerization and can effectively inhibit mitosis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a quinazoline compound. Background technique [0002] Mitosis is an essential step in cell proliferation. The body makes mitosis orderly and controllable through strict and precise regulation mechanism. Studies have shown that mitotic regulation disorder plays an important role in diseases caused by abnormal cell proliferation. The spindle and related structures during cell division are mainly composed of microtubules. Microtubules are composed of tubulin. Clinical application has proved that the mitosis inhibitor targeting tubulin activity is one of the most effective anti-cell hyperproliferation drugs. [0003] Research has shown that there are a number of compounds that interfere with tubulin function. They are mitotic inhibitors that inhibit cell proliferation by affecting the polymerization of spindle microtubules. Usually microtubule active compoun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/517A61P37/00A61P29/00A61P19/08A61P3/00A61P25/00A61P9/00A61P37/08A61P11/06A61P17/06A61P19/02A61P17/00A61P21/04A61P3/10A61P1/00A61P1/16A61P7/06A61P13/12A61P11/00A61P7/00C07D239/88
Inventor 俞强龙亚秋
Owner XIANGBEI WELMAN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com